Advertisement

Clinical Management of Patients Infected with Highly Pathogenic Microorganisms

  • Thomas KratzEmail author
  • Bruria Adini
  • August Stich
  • René Gottschalk
Chapter

Abstract

The clinical management of high consequence infectious diseases (HCID) poses an immense challenge, seen largely varying standards in terms of infection prevention control (IPC) as well as in quality of clinical care. This chapter gives an overview of possible treatment as well as IPC options. Lessons learned within the German Permanent Working Group of Competence and Treatment Centres for highly infectious, life-threatening diseases (STAKOB) are taken into account.

Keywords

Clinical management HCID STAKOB Isolation 

References

  1. 1.
    Stone. The “worried well” response to CBRN events: analysis and solutions. Defense technical information center. 2007.Google Scholar
  2. 2.
    CDC. Lassa fever confirmed in death of U.S. Traveler returning from Liberia [Online]. 2015. https://www.cdc.gov/vhf/lassa/announcements/death-of-us-traveler-returning-from-liberia.html. Accessed 18 July 2017.
  3. 3.
    Maisa. Federal state level management of an imported Lassa fever case to North Rhine-Westphalia, Germany, March 2016. Int J Infect Dis. 2017.Google Scholar
  4. 4.
    Raabe. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017;65:855–9.CrossRefGoogle Scholar
  5. 5.
    Negredo. Autochtonous crimean-congo hemorrhagic fever in Spain. N Engl J Med. 2017;377:154–61.CrossRefGoogle Scholar
  6. 6.
    Schilling S. Isolation facilities for highly infectious diseases in Europe – a cross-sectional analysis in 16 countries. PLoS One. 2014;9(10):e100401.CrossRefGoogle Scholar
  7. 7.
    McLean. The politics of fear. 2017.Google Scholar
  8. 8.
    Sagripanti. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Arch Virol. 2015;155:2035–9.CrossRefGoogle Scholar
  9. 9.
    RKI. Rahmenkonzept Ebolafieber [Online]. 2014. http://www.rki.de/DE/Content/InfAZ/E/Ebola/Rahmenkonzept_Ebolafieber.html. Accessed 18 July 2017.
  10. 10.
    WHO. Clinical management of patients with viral haemorrhagic fever. A pocket guide for the front-line health worker. 2016.Google Scholar
  11. 11.
    Kratz. Ebola – the politics of fear. 2017.Google Scholar
  12. 12.
    BBK. Handbuch biologische Gefahrenlagen.Google Scholar
  13. 13.
    Leligdowicz. Ebola virus disease and critical illness. Crit Care. 2016;20(1):217.CrossRefGoogle Scholar
  14. 14.
    Garske. Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013–2016. 2017.Google Scholar
  15. 15.
    Jeffs. The Médecins Sans Frontières Intervention in the Marburg Hemorrhagic Fever Epidemic, Uige, Angola, 2005. I. Lessons Learned in the Hospital. 2007.Google Scholar
  16. 16.
    Martini. Über eine bisher unbekannte, von Affen eingeschleppte Infektionskrankheit: Marburg-Virus-Krankheit. DMW. 1968.Google Scholar
  17. 17.
    Kreuels. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394–401.CrossRefGoogle Scholar
  18. 18.
    Wolf. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2014;385:1428–35.CrossRefGoogle Scholar
  19. 19.
    Guery. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet. 2013.Google Scholar
  20. 20.
    Linden. ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and function and health-related quality of life. Acta Anesthesiol Scand. 2009;53(4):489–95.CrossRefGoogle Scholar
  21. 21.
    McCormick. Lassa fever. Effective therapy with ribavirin. NEJM. 1985;314(1):20–6.CrossRefGoogle Scholar
  22. 22.
    WHO. Neglected tropical diseases [Online]. 2017. http://www.who.int/neglected_diseases/diseases/en/. Accessed 19 July 2017.
  23. 23.
    Poland. Treatment of plague. 1999.Google Scholar
  24. 24.
    CDC. Plague: resources for clinicians [Online]. 2015. https://www.cdc.gov/plague/healthcare/clinicians.html.
  25. 25.
    Titball. Vaccination against bubonic and pneumonic plague. Vaccine. 2001;19:4175–84.CrossRefGoogle Scholar
  26. 26.
    Olson. In vitro efficacy of brincidofovir against variola virus. 2014.Google Scholar
  27. 27.
    Durrafour. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 2010;13:181–91.Google Scholar
  28. 28.
    Keckler. The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data. Vaccine. 2013;31(45):5192–201.CrossRefGoogle Scholar
  29. 29.
    WHO. Smallpox vaccines [Online]. 2017. http://www.who.int/csr/disease/smallpox/vaccines/en/. Accessed 19 July 2017.
  30. 30.
    Tignor. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antivir Res. 1993;22(4):309–25.CrossRefGoogle Scholar
  31. 31.
    Oesterreich. Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever. PLoS Negl Trop Dis. 2014;8:e2804.CrossRefGoogle Scholar
  32. 32.
    WHO. Crimean-Congo haemorrhagic fever (CCHF) [Online]. 2017. http://www.who.int/csr/disease/crimean_congoHF/en/. Accessed 19 July 2017.
  33. 33.
    PREVAIL. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448–56.CrossRefGoogle Scholar
  34. 34.
    Sissoko. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.CrossRefGoogle Scholar
  35. 35.
    Henao-Restepro. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, 2015.  https://doi.org/10.1016/S0140-6736(13)60982-4.
  36. 36.
    Santis. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–20.CrossRefGoogle Scholar
  37. 37.
    WHO. Ebola publications: case management, infection prevention and control [Online]. 2017. http://www.who.int/csr/resources/publications/ebola/infection-prevention/en/. Accessed 19 July 2017.
  38. 38.
    Mendenhall. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. 2011.Google Scholar
  39. 39.
    Bausch. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435–51.CrossRefGoogle Scholar
  40. 40.
    Burk. Neglected filoviruses. FEMS Microbiol Rev. 2016;40:494–519.CrossRefGoogle Scholar
  41. 41.
    Klafki. Debatte Schutz vor Pandemien – Tödliche Kleinstaaterei. TAZ. 2017.Google Scholar
  42. 42.
    Bedell. Global access to medicinal products: compassionate use programs. 2010.Google Scholar
  43. 43.
    BFARM. Compassionate use programmes [Online]. 2017. http://www.bfarm.de/EN/Drugs/licensing/clinicalTrials/compUse/_node.html. Accessed 19 July 2017.
  44. 44.
    FDA. Expanded Access (Compassionate Use) [Online]. 2017. https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm. Accessed 19 July 2017.
  45. 45.
    Vetter. Ebola virus shedding and transmission: review of current evidence. J Infect Dis. 2016;214:S177–84.CrossRefGoogle Scholar
  46. 46.
    Wilson. Sierra Leone Ebola burial team attacked despite lockdown. Daily Telegraph. 2014.Google Scholar
  47. 47.
    Rakin. Yersinis pestis – Eine Bedrohung für die Menschheit. Bundesgesundheitsblatt. 2003.Google Scholar
  48. 48.
    ICRC. 2017.Google Scholar
  49. 49.
    WHO. How to conduct safe and dignified burial of a patient who has died from suspected or confirmed Ebola virus disease [Online]. 2014. http://www.who.int/csr/resources/publications/ebola/safe-burial-protocol/en/. Accessed 24 July 2017.
  50. 50.
    Macintyre 2015. Uncertainty, risk analysis and change for Ebolapersonal protective equipment guidelines. International Journal of Nursing Studies, 52(5), 899–903.Google Scholar
  51. 51.
    Kang. Use of personal protective equipment among health care personnel: Results of clinical observations and simulations. Am J Infect Control. 2016;45(1):17–23.CrossRefGoogle Scholar
  52. 52.
    Coca. Physiological and subjective evaluation of PPE using a sweating thermal manikin. Extrem Physiol Med. 2015;4(Suppl 1):A27.CrossRefGoogle Scholar
  53. 53.
    de Iaco G, Puro V, Fusco FM, Schilling S, Maltezou HC, Brouqui P, Gottschalk R, Bannister B, Brodt HR, Siikamaki H, Perronne C, Brantsaeter AB, Fjellet AL, Ippolito G. Personal protective equipment management and policies: European network for highly infectious diseases data from 48 isolation facilities in 16 European countries. Infect Control Hosp Epidemiol. 2012;33:1008–16.CrossRefGoogle Scholar
  54. 54.
    REMM. PPE classification system from OSHA and EPA [Online]. 2017. https://www.remm.nlm.gov/osha_epa_ppe.htm. Accessed 19 July 2017.
  55. 55.
    Franco. Environmental decontamination following a large-scale bioterrorism attack: federal progress and remaining gaps. Biosecur Bioterror. 2010;8(2):107–17.CrossRefGoogle Scholar
  56. 56.
    Bodurtha. Decontamination science and personal protective equipment (PPE) selection for chemical-biological-radiological-nuclear (CBRN) events. 2016.Google Scholar
  57. 57.
    CDC. Guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola [Online]. 2015. https://www.cdc.gov/vhf/ebola/healthcare-us/ppe/guidance.html. Accessed 21 July 2017.
  58. 58.
    Krauter. A systematic methodology for selecting decontamination strategies following a biocontamination event. Biosecur Bioterror. 2011;9(3):262–70.CrossRefGoogle Scholar
  59. 59.
    WHO. Decontamination and reprocessing of medical devices for healthcare facilities. 2016.Google Scholar
  60. 60.
    RKI. Hygiene requirements for the reprocessing of medical devices [Online]. 2001. https://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Hygiene_Requirements_Medical_Devices_2012.pdf?__blob=publicationFile. Accessed 21 July 2017.
  61. 61.
    RKI. Measures regarding disinfection and waste management as pertaining to an at least probable case of Ebola virus infection in Germany [Online]. 2015. http://www.rki.de/EN/Content/infections/epidemiology/outbreaks/Ebola_virus_disease/Ebola_disinfection.pdf?__blob=publicationFile. Accessed 21 July 2017.
  62. 62.
    WHO. Health care worker infections in Guinea, Liberia and Sierra Leone. A preliminary report. [Online]. 2015. http://www.who.int/csr/resources/publications/ebola/health-worker-infections/en/. Accessed 9 Apr 2018.
  63. 63.
    Sorge. Panik, Schlagzeilen und Leichenbeschau. Cicero. 2014.Google Scholar
  64. 64.
    Schmiedel. Ebolafieber in Westafrika und in Deutschland. Bundesgesundheitsblatt. 2015.Google Scholar
  65. 65.
    May. Catastrophic events versus infectious disease outbreak: distinct challenges for emergency planning. Reason Pap. 2015;37:54–64.Google Scholar
  66. 66.
    Lufthansa. Lufthansa hands over “Robert Koch” evacuation aircraft [Online]. 2014. https://www.lufthansa-technik.com/press-releases-content/-/asset_publisher/9Mf5/content/id/1563897. Accessed 24 July 2017.
  67. 67.
    Kochanek LF. Transmission and control of Lassa fever outside of Africa Accepted article – to be published. 2017.Google Scholar
  68. 68.
    WHO. Lassa fever – Germany [Online]. 2016. http://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en/. Accessed 21 July 2017.
  69. 69.
    Maisa. Federal state level management of an imported Lassa Fever case to North Rhine-Westphalia, 2016. 2016.Google Scholar
  70. 70.
    Gottschalk. Seltene hochkontagiöse und lebensbedrohliche Erkrankungen. Bundesgesundheitsblatt. 2015;58:655–6.CrossRefGoogle Scholar
  71. 71.
    Hick. Allocating scarce resources in disasters: emergency department principles. Ann Emerg Med. 2012;59:177–87.CrossRefGoogle Scholar
  72. 72.
    Waseem. Impact of operational staging to improve patient throughput in an inner-city emergency department during the novel H1N1 influenza surge: a descriptive study. Pediatr Emerg Care. 2012;28:39–42.CrossRefGoogle Scholar
  73. 73.
    Therrien. Bridging complexity theory and resilience to develop surge capacity in health systems. J Health Organ Manag. 2017;31:96–109.CrossRefGoogle Scholar
  74. 74.
    Rebmann. Best practices for healthcare facility and regional stockpile maintenance and sustainment: a literature review. Health Secur. 2017;15(4):409–17.CrossRefGoogle Scholar
  75. 75.
    Bar-El. Moral dilemmas faced by hospitals in time of war: the Rambam Medical Center during the Second Lebanon War. Med Health Care Philos. 2014;17:155–60.CrossRefGoogle Scholar
  76. 76.
    Timbie. Systematic review of strategies to manage and allocate scarce resources during mass casualty events. Ann Emerg Med. 2013;61:677–89.CrossRefGoogle Scholar
  77. 77.
    Alfred. Preparing for disasters: education and management strategies explored. Nurse Educ Pract. 2015;15:82–9.CrossRefGoogle Scholar
  78. 78.
    Bruria. Case study–Israel. Dordrecht: Springer; 2013.CrossRefGoogle Scholar
  79. 79.
    Culley. A review of the literature on the validity of mass casualty triage systems with a focus on chemical exposures. Am J Disaster Med. 2014;9:137.CrossRefGoogle Scholar
  80. 80.
    Albanese. Clinical guidelines for responding to chemical, biological, radiological, nuclear and trauma/burn mass casualty incidents: quick reference guides for emergency department staff. J Bus Contin Emer Plan. 2014;8:122–33.PubMedGoogle Scholar
  81. 81.
    DOH U. Chapter 2: Health and medical care delivery in a mass casualty event. 2011. Google Scholar
  82. 82.
    Curnow. Mass casualty triage performance assessment tool. No. ARI/FB-RP-2015-02. Army Research Institute for the Behavioral and Social Sciences Fort Belvoir, VA, 2015. 2014. Google Scholar
  83. 83.
    Barilan. Triage in disaster medicine: ethical strategies in various scenarios. Dordrecht: Springer; 2014. p. 49–63.Google Scholar
  84. 84.
    Landsdowne. Recent advances in medical device triage technologies for chemical, biological, radiological, and nuclear events. Prehosp Disaster Med. 2015;30(3):320–3.CrossRefGoogle Scholar
  85. 85.
    Russo. Mass casualty disasters: who should run the show? J Emerg Med. 2015;48:685–92.CrossRefGoogle Scholar
  86. 86.
    Bannister B. Framework for the design and operation of high level isolation units: consensus of the European network of infectious diseases. Lancet Inf Dis. 2009;9(1):45–56.CrossRefGoogle Scholar
  87. 87.
    Miller. Implementing a negative-pressure isolation ward for a surge in airborne infectious patients. Am J Infect Control. 2017;45:652–9.CrossRefGoogle Scholar
  88. 88.
    Rubinson. Augmentation of hospital critical care capacity after bioterrorist attacks or epidemics: recommendations of the working group on emergency mass critical care. Crit Care Med. 2005;33:2393.CrossRefGoogle Scholar
  89. 89.
    Kearns. Hospital bioterrorism planning and burn surge. Biosecurity Bioterrorism Biodefense Strateg Pract Sci. 2014;12:20–8.CrossRefGoogle Scholar
  90. 90.
    Gonsalves. Panic, paranoia, and public health—the AIDS epidemic’s lessons for Ebola. N Engl J Med. 2014;371:2348–9.CrossRefGoogle Scholar
  91. 91.
    Djalali. TIER competency-based training course for the first receivers of CBRN casualties: a European perspective. Eur J Emerg Med. 2016;24:371–6.CrossRefGoogle Scholar
  92. 92.
    Lewis. Mass casualty incident management preparedness: a survey of the American College of Surgeons Committee on Trauma. Am Surgeion. 2016;82:1227–31.Google Scholar
  93. 93.
    Siegel. Prioritization of pediatric chemical, biological, radiologic, nuclear, and explosive disaster preparedness education and training needs. Clin Pediatr Emerg Med. 2014;48:685–92.Google Scholar
  94. 94.
    Pesiridis. Development, implementation and evaluation of a disaster training programme for nurses: a switching replications randomized controlled trial. Nurse Educ Pract. 2015;15:63–7.CrossRefGoogle Scholar
  95. 95.
    Kim JH. Learning from UK disaster exercises: policy implications for effective emergency preparedness. Disasters. 2014;38:846–57.CrossRefGoogle Scholar
  96. 96.
    Quevillon. Helping the helpers: assisting staff and volunteer workers before, during, and after disaster relief operations. J Clin Psychol. 2016;72(12):1348–63.CrossRefGoogle Scholar
  97. 97.
    Barry. A literature review on effective risk communication for the prevention and control of communicable diseases in Europe. J Health Commun. 2013:1–19.Google Scholar
  98. 98.
    Kern. Global epidemics, pandemics, terrorism: risk assessment and European responses. ISPSW Strateg Ser. 2016.Google Scholar
  99. 99.
    Penta. Of earthquakes and epidemics: examining the applicability of the all-hazards approach in public health emergencies. Risk Hazards Crisis Public Policy. 2017;8:48–67.CrossRefGoogle Scholar
  100. 100.
    Barrelet. Unresolved issues in risk communication research: the case of the H1N1 pandemic (2009–2011). Influenza Other Respir Viruses. 2013;7(s2):114–9.CrossRefGoogle Scholar
  101. 101.
    Farrar. The Ebola emergency—immediate action, ongoing strategy. N Engl J Med. 2014;371:1481–95.CrossRefGoogle Scholar
  102. 102.
    Dickmann. Biological risks to public health: lessons from an international conference to inform the development of national risk communication strategies: report of an international conference on risk communication strategies before, during, and after public health emergencies, Rabat, Morocco, October 22–23, 2015. Health Secur. 2016;14:433–40.CrossRefGoogle Scholar
  103. 103.
    Fisman. Nuanced risk assessment for emerging infectious diseases. Lancet. 2014;383:189.CrossRefGoogle Scholar
  104. 104.
    Ruggiero. CBRN communication scorecard. Behavior and communication in CBRN crisis: findings and recommendations in case of chemical, biological, radiological, and nuclear attacks on society. Lengerich: Pabst Science; 2015.Google Scholar
  105. 105.
    Lipsitch. If a global catastrophic biological risk materializes, at what stage will we recognize it? Health Secur. 2017;15.  https://doi.org/10.1089/hs.2017.0037
  106. 106.
    Jansen. Biological warfare, bioterrorism, and biocrime. Clin Microbiol Infect. 2014;20:488–96.CrossRefGoogle Scholar
  107. 107.
    Lioy. Preparedness and response to chemical and biological threats: the role of exposure science. Ann N Y Acad Sci. 2016;1378:108–17.CrossRefGoogle Scholar
  108. 108.
    Watson. Expert views on biological threat characterization for the US government: a delphi study. Risk Anal. 2017;37(12):2389–404.CrossRefGoogle Scholar
  109. 109.
    Rainisch. Modeling tool for decision support during early days of an anthrax event. Emerg Infect Dis. 2017;23:46.CrossRefGoogle Scholar
  110. 110.
    Grow. The challenge of hospital infection control during a response to bioterrorist attacks. Biosecurity Bioterrorism Biodefense Strateg Pract Sci. 2003;1:215–20.CrossRefGoogle Scholar
  111. 111.
    Lor. Key ethical issues discussed at CDC-sponsored international, regional meetings to explore cultural perspectives and contexts on pandemic influenza preparedness and response. Int J Health Policy Manag. 2016;5:653.CrossRefGoogle Scholar
  112. 112.
    WHO. Guidance for managing ethical issues in infectious disease outbreaks. [Online]. 2016. http://apps.who.int/iris/handle/10665/250580. Accessed 22 Aug 2017.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Thomas Kratz
    • 1
    Email author
  • Bruria Adini
    • 1
  • August Stich
    • 1
  • René Gottschalk
    • 1
  1. 1.Federal Information Centre for Biological Threats and Special PathogensRobert Koch-InstituteBerlinGermany

Personalised recommendations